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Objectives: Persistent MRSA infections are especially relevant to endovascular infections and correlate with
suboptimal outcomes. However, the virulence signatures of Staphylococcus aureus that drive such persistence
outcomes are not well defined. In the current study, we investigated correlations between accessory gene regu-
lator (agr) activation and the outcome of vancomycin treatment in an experimental model of infective endocar-
ditis (IE) due to MRSA strains with different agr and clonal complex (CC) types.
Methods: Twelve isolates with the four most common MRSA CC and agr types (CC5-agr II, CC8-agr I, CC30-agr III
and CC45-agr I) were evaluated for heterogeneous vancomycin-intermediate S. aureus (hVISA), agr function,
agrA and RNAIII transcription, agr locus sequences, virulence and response to vancomycin in the IE model.
Results: Early agr RNAIII activation (beginning at 2 h of growth) in parallel with strong d-haemolysin production
correlated with persistent outcomes in the IE model following vancomycin therapy. Importantly, such treatment
failures occurred across the range of CC/agr types studied. In addition, these MRSA strains: (i) were vancomycin
susceptible in vitro; (ii) were not hVISA or vancomycin tolerant; and (iii) did not evolve hVISA phenotypes or per-
turbed d-haemolysin activity in vivo following vancomycin therapy. Moreover, agr locus sequence analyses
revealed no common point mutations that correlated with either temporal RNAIII transcription or vancomycin
treatment outcomes, encompassing different CC and agr types.
Conclusions: These data suggest that temporal agr RNAIII activation and agr functional profiles may be useful
biomarkers to predict the in vivo persistence of endovascular MRSA infections despite vancomycin therapy.
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Introduction
Staphylococcus aureus is the most common cause of endovascu-
lar infections, including infective endocarditis (IE), and the second
most frequent cause of bacteraemia.1,2 Invasive infections such
as IE, particularly those caused by MRSA strains, are associated
with a high mortality (15%–40%).3 – 5 In addition, the high rates
of clinical failure on vancomycin (even with CLSI-defined ‘suscep-
tible’ strains) and the growing problem of daptomycin non-
susceptibility, have further complicated the management of
patients with invasive MRSA infections.5,6
The pathogenesis of S. aureus is largely controlled by regulatory
networks composed of: (i) global regulons (e.g. sarA); (ii)
two-component regulatory systems (e.g. agr and saeRS); and (iii)
downstream effector genes (e.g. hla).7,8 Central to the orchestra-
tion of this regulatory network is the quorum-sensing operon agr.
Of note, agr consists of two transcription domains, RNAII and
RNAIII, driven by the divergent promoters P2 and P3, respect-
ively.9 RNAII encodes a quorum-sensing system and RNAIII is
the effector molecule of the agr system. In vitro, agr down-
regulates many pivotal cell surface proteins involved in tissue
colonization while up-regulating exoproteins associated with
host cell damage.9 In vitro studies have suggested that the tem-
poral activation of agr is an important determinant of agr func-
tionality; i.e. earlier versus later agr activation correlates with
intact versus attenuated function, respectively.6,10 As most of
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the available data on agr expression and regulatory impacts have
only been obtained in vitro, an important question relates to how
such temporal regulatory functions translate to the in vivo scen-
ario, particularly in the context of endovascular MRSA infections
that persist versus resolve after antibiotic treatment.
We previously demonstrated a positive correlation between
early-onset agr RNAIII activation and resistance to vancomycin
treatment in an experimental model of IE.6 Although intriguing,
these initial studies were somewhat limited: (i) they were
restricted to strains from only two clonotypes (CC45-agr I and
CC5-agr II); and (ii) they did not account for other genotypic influ-
ences on outcomes such as variations of agr types. Thus, it
remains unknown whether the relationship between the temporal
RNAIII activation profiles and antibiotic treatment outcomes is CC
and/or agr type-specific in endovascular infection. Therefore, in
the current investigation, we sought to validate and extend
upon our prior observations, using a broad range of the most com-
mon clonotypes causing invasive MRSA infections such as IE.11 – 13
The overarching goals of this project were: (i) to assess key genetic
strategies used by MRSA to resist antimicrobial therapy (e.g.
early agr activation); and (ii) to identify novel biomarkers that
correlate with the phenotype of persistent endovascular MRSA
infection.
Materials and methods
Bacterial strains and growth conditions
In the current study, we selected two CC5-agr II, four CC8-agr I and two
CC30-agr III MRSA clinical isolates; in addition, we chose four previously
sequenced reference strains of S. aureus (one for each CC type, including
CC45) as relevant genetic controls (B. N. Kreiswirth, unpublished data;
Table 1). These strains were from a multinational clinical trial collection
and other sources14 and were pre-selected based on their relative
d-haemolysin activities as outlined below. Unless otherwise stated, all
S. aureus strains were grown at 378C either in tryptic soy broth (TSB;
Difco) or TSB agar plates. Stocks were kept at –808C in brain heart infusion
(Difco) broth supplemented with 10% glycerol.
agr, SCCmec, spa, CC typing and agr locus sequence
The agr group was determined by a multiplex PCR assay described else-
where,15 while the SCCmec type was examined using a multiplex real-time
PCR published previously.16 The spa typing was conducted according to a
protocol described before; the corresponding clonal complex (CC) of each
strain was inferred based on the spa types.17 Full-length agr locus sequen-
cing was performed as previously described.6
MICs, kill curves and population analyses
The determination of vancomycin MICs was conducted by broth microdi-
lution as recommended by the CLSI.18 In vitro, vancomycin kill curves and
population analyses were carried out to detect vancomycin tolerance and
heterogeneous vancomycin-intermediate S. aureus (hVISA), respect-
ively.19 All in vitro experiments were performed at least twice for each
strain on different days.
d-Haemolysin activity
d-Haemolysin activity was assayed by cross-streaking the test strains per-
pendicularly to RN4220, a strain that is a hyperproducer of b-haemolysin
but that does not produce a-haemolysin.6 Strains SH1000 and SH1001
(the agr mutant of SH1000) were used as positive and negative controls,
respectively. d-Haemolytic activity was denoted by an enhanced area of
haemolysis at the intersection of the RN4220 streak and the test strain
streaks as described.6 In addition, the d-haemolysin activity of each strain
was semi-quantitatively scored by two investigators involved in this study
who were blinded to the isolate numbers, as follows: non-detectable,
weak and strong. All experiments were conducted at least three times
on separate days.
agrA and RNAIII transcription by quantitative RT–PCR
It is well accepted that transcription from P2 and P3 occurs in a strictly
AgrA-dependent manner. However, recent studies have identified that
core virulence factors in various S. aureus strains depend either on
RNAIII or AgrA for regulation.20 Thus, in the current study, we defined
the temporal transcription profiles of both agrA and RNAIII (as surrogate
biomarkers of global agr operon activation) by qRT–PCR analyses.6 In brief,
Table 1. Genotypic characteristics of and vancomycin MICs for study isolates
Strains CC agr group SCCmec spa type (motif) Source Location (reference) Year Vancomycin MIC (mg/L)
Clinical isolates
26997 5 II IV 2 (TJMBMDMGMK) blood USA 2009 1.0
31190 5 II II 2 (TJMBMDMGMK) sputum USA 1996 1.0
29439 8 I IV 1037 (YHGFMBO) SSTI Colombia 2008 1.0
30279 8 I VIII 1 (YHGFMBQBLO) SSTI USA 2010 2.0
31082 8 I IV 139 (YGFMBLO) blood USA 2009 2.0
30568 8 I IV 7 (YHGCMBQBLO) blood USA 2010 2.0
33367 30 III IV 19 (XKAKAOMQ) wound Romania 2005 1.0
17130 30 III II 16 (WGKAKAOMQQQ) SSTI USA 2007 1.0
Reference strains
36096 5 II IV 2 (TJMBMDMGMK) blood USA 2010 2.0
19069 (USA300-FPR3757) 8 I IV 1 (YHGFMBQBLO) abscess USA ND 2.0
22033 (WBG10049) 30 III IV 19 (XKAKAOMQ) ND Australia 1999 2.0
21314 45 I MSSA XKAKBEMBKB blood France 2002 2.0
ND, no data available; SSTI, skin and soft tissue infection.
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overnight cultures of S. aureus were diluted 100-fold in fresh TSB medium
and grown at 378C in a shaking incubator. Cells were harvested at 2, 3, 4, 8
and 24 h of growth, representing the early-, mid-, late-, post-exponential
phases, and the stationary phase, respectively. Quantitative real-time PCR
was carried out using an ABI Prism 7000 instrument (Applied Biosystems)
and the SYBR green PCR master mix (Applied Biosystems). Reaction
mixtures were prepared using the 100 nM primers listed in Table 2. A well-
characterized gene, gyrB, was used as an internal control.6,21 Relative tar-
get gene expression was calculated as the differences in cycle thresholds
(DCT) (gyrBCT – target gene CT) for all samples.
21 qRT–PCR experiments
were performed using at least two biological replicates, with each one
tested in triplicate.
Experimental rabbit IE model
It was important to assess the potential translatability of our in vitro
findings in a realistic and relevant infection model in vivo. A catheter-
induced model of IE affecting the aortic valve in rabbits was used to
study the composite metrics of virulence and responsiveness to vancomy-
cin therapy among the S. aureus strains used in the study.6,22 The animals
were maintained in accordance with the American Association for
Accreditation of Laboratory Animal Care criteria. The Animal Research
Committee (IACUC) of the Los Angeles Biomedical Research Institute at
Harbor-UCLA Medical Center approved all the animal studies.
To assess the relative intrinsic virulence of the strains, infected animals
(105 cfu, representing the ID95 inoculum) were euthanized at 24 h after
intravenous challenge by a rapid intravenous injection of sodium pento-
barbital (200 mg/kg; Abbott Laboratories). The cardiac vegetations, kid-
neys and spleen were then removed under sterile conditions and
quantitatively cultured.6,22 The tissue densities of S. aureus were calcu-
lated as the mean log10 cfu/g (+SD).
To assess the response to vancomycin therapy, animals with IE were
randomized at 24 h post-infection to receive either no therapy (controls)
or vancomycin therapy (15 mg/kg, intravenously, twice daily for 3 days).
This is a standard effective dose of vancomycin in the experimental
model of IE caused by vancomycin-susceptible staphylococcal strains.6,22
At 24 h after the last dose of vancomycin, the animals were sacrificed and
the target tissues removed and quantitatively cultured as described above.
In vivo population analysis
An in vivo population analysis assay was performed to determine whether
the in vivo emergence of the hVISA phenotype might explain the subse-
quent impact on either the virulence of the organism or the responsive-
ness to the antibiotic. A volume of 10 mL of vegetation homogenate was
plated directly onto TSA agar plates containing serial concentrations of
vancomycin (0.125–8 mg/L) as described above.
In vivo assessment of d-haemolysin activity
Similar to the hVISA analyses above, it was important to test whether
d-haemolysin activity among the infecting strains was altered during
in vivo passage. Thus, an in vivo assessment of d-haemolysin production
was performed by cross-streaking vegetation homogenates perpendicu-
larly to RN4220 as described above.
Statistical analysis
To compare tissue counts of S. aureus in vancomycin-treated versus
untreated control animals, univariate analyses were performed using
the Student’s t-test. P values of ,0.05 were considered statistically
significant.
Results
In vitro susceptibility to vancomycin
Vancomycin MICs for the study strains were all in the susceptible
range as outlined by the CLSI guidelines (Table 1). In vitro popula-
tion analyses of the isolates revealed no hVISA phenotypes
[Figure S1 (A1, B1 and C1), available as Supplementary data at
JAC Online; data not shown for the four reference strains]. Killing
curve assays demonstrated no evidence of in vitro vancomycin
tolerance (data not shown).
In vitro d-haemolysin activities
A total of two CC5, three CC8, one CC30 and one CC45 isolates pro-
duced strong zones of haemolysis due to d-haemolysin activity
(Figure S2). In contrast, the other five strains exhibited weak or
non-detectable d-haemolysin production (Figure S2).
agrA and RNAIII transcriptions
The initiation of transcription of RNAIII strictly relies upon the
expression of agrA, in an RNAII-dependent manner. Our data
support these observations as the transcription of agrA was
observed in all strains with RNAIII expression except strain
30568 (Figure 1a and b for agrA and RNAIII expression, respect-
ively). In addition, a rapid increase in RNAIII transcription occurred
in the post-exponential growth phase, concomitant with a cell-
density-dependent expression of the agr operon (Figure 1b).
More importantly, the seven strains with strong d-haemolysin
activity (one CC5, two CC8 and one CC30 clinical isolate, and
three of the four reference strains) exhibited a relatively early
onset of RNAIII expression, beginning at 2 –3 h of growth
(Figure 1b). The other five strains had very low-level or no RNAIII
transcripts detectable before 4 h (Figure 1b). These data indicated
that the early onset of RNAIII transcription correlated with strong
d-haemolysin production, independent of the CC/agr genotype. As
the growth rates for all the study strains were similar, the
observed differences in the onset of RNAIII expression were not
due to differences in growth dynamics (data not shown).
agr locus sequence analyses
We sequenced the entire agr locus of the 12 study strains (includ-
ing RNAII, RNAIII and their respective promoter regions; Table 3).
The results in two CC5-agr II strains (exhibiting strong
d-haemolysin activity and an early onset of RNAIII activation)
revealed identical agr locus sequences but these differed from
the agr sequence reference strain N315 by only one nucleotide
between agrD and agrC. The agr sequence of another CC5-agr II
strain, 31190 (having weak d-haemolysin activity and a late
Table 2. Primers used in this study
Primer Sequence (5′ –3′) Reference
gyrB-F CGCAGGCGATTTTACCATTA 6
gyrB-R GCTTTCGCTAGATCAAAGTCG 6
RNAIII-F GCCATCCCAACTTAATAACCA 6
RNAIII-R TGTTGTTTACGATAGCTTACATGC 6
agrA-F CGAAGACGATCCAAAACAAAG 48
agrA-R ATGTTACCAACTGGGTCATGC 48
agr RNAIII activation in persistent MRSA endocarditis
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Figure 1. In vitro expression of agrA (a) and RNAIII (b) in all S. aureus strains studied at 2, 3, 4, 8 and 24 h of growth. Data were obtained by RT–PCR and
relative transcript levels of agrA and RNAIII represent the mean (+SD) of at least two biological replicates (fold changes versus gyrB). Strains with strong
d-haemolysin activity are underlined.
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onset of expression of RNAIII), differed by one nucleotide from
these two strains within the intergenic region between hld and
agrB. However, it is not clear whether this agr mutational event
was related to the different d-haemolysin activity observed in
this strain set. Two CC8-agr I (31082 and 30568) and two
CC30-agr III (33367 and 22033) strains with different
d-haemolysin activities had the same agr sequence as their
respective reference strains. Taken together, these results indicate
that no consensus genetic determinants in the agr locus were
identified as being predictive of agr functionality crossing different
CC and agr genetic types.
Intrinsic virulence and responsiveness to vancomycin in
the IE model
The intrinsic virulence of the study strains in the IE model (based
on achievable target-tissue counts of S. aureus) was similar
among the study isolates (Figure 2). Therefore, there was no obvi-
ous relationship between the above agr metrics, CC types and
intrinsic virulence of the strains studied in this model of infection.
In contrast, our data revealed a direct correlation between
temporal agr RNAIII expression in vitro and vancomycin therapy
in vivo. For example, the vancomycin therapy of animals infected
with the five strains that exhibited a late onset of RNAIII and weak
or no d-haemolysin activity in vitro (clinical isolates 31190, 30279,
30568 and 17130, and reference strain 22033) resulted in uni-
form and highly significant reductions in MRSA counts in all the
target tissues (Figure 2). Thus, we observed a ≥5 log10 cfu reduc-
tion in the vegetation counts and ≥3 log10 cfu reduction in the
kidney and spleen counts compared with the respective untreated
control groups (P,0.0001 for all strains and all three target tis-
sues). In contrast, animals with IE caused by strains with strong
d-haemolysin activity and an early onset of RNAIII transcription
showed one of two outcomes: (i) no response to vancomycin
treatment, with residual target-tissue MRSA densities similar to
those in the respective untreated controls (the 33367 clinical iso-
late and the 36096 reference strain; Figure 2); or (ii) a,3 log10 cfu
reduction in target-tissue counts (clinical isolates 26997, 29439
and 31082, and reference strains 19069 and 21314; Figure 2).
Importantly, there was no significant difference in the weight
of the vegetations between the groups (data not shown).
Therefore, the microbiological difference in vegetation counts
was not impacted by the differences in structure or size of the
vegetations.
In vivo population analyses
Figure S1 (A2, B2, B3 and C2) shows the in vivo population analyses
from vegetation homogenates of the study clinical isolates surviv-
ing vancomycin therapy in the IE model (data not shown for the
four reference strains). No subpopulations that were hetero-
resistant to vancomycin were observed in the vegetations from
any animals (Figure S1; data not shown for the control animals
without treatment). We were unable to test for potential hVISA
phenotypes in strains highly susceptible to vancomycin therapy
in the IE model due to the low residual bacterial counts of the
vegetations (,3 log10 cfu/g).
In vivo d-haemolysin activity
No changes in profiles of d-haemolysin activity were observed in
any isolates after passage through the IE model (Figure S2; data
not shown for the four reference strains).
Discussion
S. aureus is a highly adaptable bacterium capable of dynamic
changes in its virulence and resistance phenotypes in the face
Table 3. agr locus sequence, d-haemolysin and RNAIII activation of the study strains
Strains CC
agr
group
d-Haemolysin
activity
RNAIII
activation agr sequence Reference strains
Clinical isolates
26997 5 II strong early TA between agrD and agrC N315
31190 5 II weak late TA between agrD and agrC, GA between hld
and agrB,
N315
29439 8 I strong early TA in agrC (F309I) USA 300
30279 8 I weak late AG in RNAIII, TA in P3 promoter region, AT
in agrB (I171F), TA in agrC (F309I)
USA 300
31082 8 I strong early TA in P3 promoter region, TA in agrC (F309I) USA300
30568 8 I none none TA in P3 promoter region, TA in agrC (F309I) USA300
33367 30 III strong early RNAIII 386A del, agrC (R55G) MRSA 252
17130 30 III weak late none MRSA 252
Reference strains
36096 5 II strong early TA between agrD and agrC N315
19069
(USA300-FPR3757)
8 I strong early none USA300
22033 (WBG10049) 30 III weak late RNAIII 386A del, agrC (R55G) MRSA 252
21314 45 I strong early none CA-347 (CP006044)
agr RNAIII activation in persistent MRSA endocarditis
1447
JAC
Downloaded from https://academic.oup.com/jac/article-abstract/70/5/1443/690241
by University of Zurich user
on 24 July 2018
–VAN   +VAN
Vegetations
0
2
4
P < 0.05
6
Lo
g 1
0 
cf
u/
g 
tis
su
e
8
10
12(a)
(b)
(c)
26997 CC5 (agr II)
–VAN   +VAN
Kidneys
–VAN   +VAN
Spleen
–VAN   +VAN
Vegetations
0
2
4
6
Lo
g 1
0 
cf
u/
g 
tis
su
e
8
10
12
29439 CC8 (agr I)
–VAN   +VAN
Kidneys
–VAN   +VAN
Spleen
–VAN   +VAN
Vegetations
0
2
4
6
Lo
g 1
0 
cf
u/
g 
tis
su
e
8
10
12
31082 CC8 (agr I)
–VAN   +VAN
Kidneys
–VAN   +VAN
Spleen
–VAN   +VAN
Vegetations
0
2
4
6
Lo
g 1
0 
cf
u/
g 
tis
su
e
8
10
12
30279 CC8 (agr I)
–VAN   +VAN
Kidneys
–VAN   +VAN
Spleen
–VAN   +VAN
Vegetations
0
2
4
6
Lo
g 1
0 
cf
u/
g 
tis
su
e
8
10
12
30568 CC8 (agr I)
–VAN   +VAN
Kidneys
–VAN   +VAN
Spleen
–VAN   +VAN
Vegetations
0
2
4
6
Lo
g 1
0 
cf
u/
g 
tis
su
e
8
10
12 33367 CC30 (agr III)
–VAN   +VAN
Kidneys
–VAN   +VAN
Spleen
–VAN   +VAN
Vegetations
0
2
4
6
Lo
g 1
0 
cf
u/
g 
tis
su
e
8
10
12 17130 CC30 (agr III)
–VAN   +VAN
Kidneys
–VAN   +VAN
Spleen
–VAN   +VAN
Vegetations
0
2
4
6
Lo
g 1
0 
cf
u/
g 
tis
su
e
8
10
12
31190 CC5 (agr II)
–VAN   +VAN
Kidneys
–VAN   +VAN
Spleen
P < 0.000001
P < 0.0001
P < 0.01P < 0.01
P < 0.0001
P < 0.000001
P < 0.0000001
P < 0.0001
P < 0.0001
P < 0.0000001
P < 0.00000001
P < 0.000001 P < 0.000001
P < 0.0001
P < 0.0000001
P < 0.0001 P < 0.001P < 0.00001
P < 0.0001
P < 0.000001
Figure 2. S. aureus densities in the target tissues in the IE model in the presence versus absence of vancomycin therapy for 3 days (panels a, b and c
represent clinical CC5, CC8 and CC30 S. aureus strains, respectively, and panel d represents four reference strains). Each dot represents one rabbit and the
horizontal black bars indicate the means of the observations. Strains with strong d-haemolysin activities are underlined. VAN, vancomycin.
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of exposure to host defences or administered antibiotics. As a
result of such capabilities, ‘persistent’ endovascular MRSA infec-
tions frequently occur despite seemingly appropriate antibiotic
therapy. This reality represents a daunting and increasingly life-
threatening clinical syndrome. The fundamental phenotypic and
genotypic virulence and resistance ‘signatures’ of S. aureus that
drive such persistent clinical outcomes are not well defined.
Thus, the identification of potential biomarkers that specifically
characterize persistent S. aureus strains is urgently needed. The
current study was designed to contribute new insights that
might help to address this void in knowledge.
The agr operon plays an important and complex role in the
pathogenesis of MRSA infections.9,23,24 In addition, polymorph-
isms in agrD and agrC have been utilized to genotypically define
the major S. aureus agr groups (I–IV).25 – 27 Several previous stud-
ies have suggested an association of specific agr groups with dis-
tinct clinical syndromes involving S. aureus.25,26 For example, agr
group II has been associated with a poor response to vancomycin
therapy in patients with MRSA infections.28 Of note, such linkage
of the agr group II genotype to suboptimal treatment outcomes
has not been verified in more recent reports using a rabbit model
of IE.6 Interestingly, in addition to agr genotypes, four CC types
(CC5, CC8, CC30 and CC45) are reported to predominate in serious
S. aureus infections.29,30 Moreover, distinct CC types show a differ-
ing potential to cause invasive disease.31 For instance, CC5 and
CC30 have been reported to be associated with more severe infec-
tions.11 Furthermore, Miller et al.32 recently correlated the CC22
genotype with cases of IE. Conversely, Feil et al.33 reported that
disease isolates were equally represented across all CC types, sug-
gesting that the link between CC genotype and the propensity to
cause specific disease syndromes is at best inconsistent. The
above examples illustrate how the genotypic and phenotypic
plasticity of S. aureus is likely to afford a variety of survival strat-
egies and advantages in distinct host defence settings. Thus,
rather than seeking a single gene or distinct host phenotype
that enables persistence, our work seeks to identify and validate
more integrated signals of adaptive responses in S. aureus that are
associated with virulence and antimicrobial resistance.
Vancomycin has remained a stalwart for the treatment of inva-
sive MRSA infections. We recently studied the relationship of agr
RNAIII expression with vancomycin treatment outcomes in
experimental IE due to 10 clinical MRSA strains with two distinct
genetic backgrounds (CC5-agr II and CC45-agr I). These investiga-
tions demonstrated that early-onset agr RNAIII activation corre-
lated with failures of vancomycin treatment in this model.6
Therefore, our current studies were designed to further investigate
the question of whether this putative correlation between the
temporal agr RNAIII activation profiles and the outcome of anti-
biotic treatment is CC-agr type specific or more generic across
CC-agr types. In this regard, our strategy was strengthened by
the use of clinical MRSA isolates representing the most common
CC-agr types (CC5-agr II, CC8-agr I and CC30-agr III) in compari-
son with four respective S. aureus reference strains.
Several key insights emerged from this study. We found that
the overall temporal transcription of RNAIII was strain dependent
but CC/agr type independent. Most importantly, consistent with
our previous observation,6 we found that early-onset agr RNAIII
activation (beginning at 2–3 h of growth) significantly correlated
with reduced vancomycin efficacy in experimental IE. The exact
mechanism(s) by which earlyagractivation provides the organism
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with reduced vancomycin susceptibility in vivo in this model is yet
to be defined. However, in this regard, we have recently confirmed
that strains exhibiting early RNAIII activation (which are vanco-
mycin non-responders in the IE model) differed substantially
from the strains showing later RNAIII expression (vancomycin
responders in the same model) in terms of: (i) lower vancomycin
binding; (ii) increased intrinsic biofilm formation; (iii) higher sur-
vival in the presence of vancomycin within biofilms in the presence
or absence of catheters; (iv) enhanced biofilm formation during
vancomycin exposure below the MIC; (v) significantly greater
damage to endothelial cells;19,34 and (vi) reduced killing by certain
host defence antimicrobial peptides.35 Each of these differences
may contribute individually or in combination to the strain-
specific vancomycin treatment outcomes in the IE model.
Importantly, we performed an in vitro growth assay and found
that all the study strains had similar growth rates. In addition,
all the study isolates had similar fitness profiles in the IE model:
(i) all strains had the same ID95 for the induction of IE (10
5 cfu/
animal); and (ii) the intrinsic virulence of the study strains in the
IE model, based on achievable target-tissue counts of S. aureus,
was similar among the study isolates (Figure 2). These data indi-
cate that the observed differences in the onset of agr RNAIII
expression and treatment outcomes were not due to differences
in in vivo growth dynamics. In contrast to our observations, other
studies have suggested that agr dysfunction can be associated
with decreased vancomycin efficacy and persistent bacteraemia
in MRSA infections.5,27,36 – 38 For instance, Fowler et al.5 reported
that d-haemolysin activity was less common in persistent versus
resolving MRSA isolates. However, these differences did not reach
statistical significance.5 In addition, these conflicting findings may
reflect geographical or other epidemiological patterns. Of note, it
has been reported that even though the lack of d-haemolysin pro-
duction is a phenotypic marker of agr dysfunction,5,39,40 its
absence does not necessarily correlate with the absence of
RNAIII transcripts.41
Paralleling our experimental model outcomes, clinical treat-
ment failures with vancomycin occur fairly commonly even with
‘vancomycin-susceptible’ S. aureus strains.42 Some studies have
suggested that an in vivo evolution of the hVISA phenotype during
therapy can be responsible for such clinical failures.43 However, in
the current study, we could not confirm hVISA development
in vivo during vancomycin therapy.
Consistent with previous studies from our laboratories6 and
others,44 – 46 we found no common or consensus SNPs within
the agr locus that predicted its temporal activation profiles and/or
functionality in vitro, or vancomycin responsiveness in experimen-
tal IE crossing different CC/agr types. In support of our findings,
other investigations have also found no differences in the
agr sequence between clinical pairs of parental vancomycin-
susceptible S. aureus strains and hVISA/VISA strains evolving
during antibiotic-persistent infection.45,46 Taken together, these
findings suggest that strain-specific gain-of-function or loss-of-
function readouts of genetic determinants in the agr locus cannot
yet be linked to agr functionality and vancomycin treatment out-
comes. This observation also implies that genotypic factors
beyond or interacting with the agr locus may play a role in adap-
tive response phenotypes with respect to virulence and antibiotic
resistance outcomes in vivo.
Our investigations have several limitations. For example, hVISA
strains were not studied in our model; such strains may be very
important as they have been associated with high frequencies
of treatment failure and persistent bacteraemia.43,47 In addition,
additional S. aureus isolates from patients with known endovascu-
lar infections should be evaluated to better understand the pre-
cise factors responsible for persistent outcomes in this clinical
context. Moreover, based on current findings, we do not know
whether the relationship between the RNAIII activation profiles
and the outcome of antibiotic treatment is ‘vancomycin specific’
or more broad range against other antimicrobials. Although this is
beyond the scope of the present study, future studies should
examine this potential correlation.
In summary, we have demonstrated that: (i) early agr RNAIII
activation, although not ‘causal’,6 is a ‘biomarker’ or ‘signature’
predictive of an antibiotic-persistent outcome; and (ii) factors out-
side the agr locus are responsible for the genetic linkage between
temporal agr RNAIII activation and the outcome of vancomycin
treatment in the IE model. The exact mechanism(s) that correlate
with the failure of vancomycin treatment remain to be fully
elucidated. Studies including whole-genome sequencing, suscep-
tibilities to the peptides involved in host defences against anti-
microbial agents (e.g. platelet microbicidal proteins and human
neutrophil peptide 1), biofilm formation, endothelial cell damage,
vancomycin binding, etc. are in progress in our laboratories to bet-
ter define these mechanism(s).
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